摘要:
The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.
摘要:
The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides which inhibit multimerization of a receptor complex comprising an IL-17R family member. Related PLAD-binding polypeptides, chimeric proteins, conjugates, nucleic acids, vectors, host cells, and methods are provided herein.
摘要:
The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.
摘要:
Method and circuit aspects for improving lock-in time following power-up in a phase-locked loop are provided. The circuit and method for providing same includes a phase-locked loop, the phase-locked loop comprising a low pass filter, and a pulse generation circuit coupled to the low pass filter. The pulse generation circuit provides a control pulse of predetermined duration to increase a voltage across the low pass filter and reduce lock-in time in the phase-locked loop following power-up. The pulse generation circuit further includes a plurality of logic gates, the plurality of logic gates including a plurality of inverters coupled to a NAND gate.
摘要:
A method and system for synchronizing a reference signal and an output signal produced by an electrical circuit, the electrical circuit comprising an analog portion and a digital portion, is disclosed. The method comprises the steps of utilizing the digital portion to produce a phase-adjusted signal and utilizing the analog portion to produce an output signal in substantially the same phase as the phase-adjusted signal. Through the use of the method and system in accordance with the present invention, the large bi-direction shift register of conventional hybrid DLLs is no longer necessary and high speed DLLs will be capable of providing high resolution deskewed clocks in a shorter amount of time. The use of the present invention also facilitates the coverage of a wider range of clock frequencies.
摘要:
This invention provides a method of computing dynamically the maximum power output to electric vehicle (EV) power train from the multiple and independently controlled battery packs to ensure safety and proper protection of the electric system. This method applies to an EV with multiple or extendable number of battery packs and provides fast computation of number of connected battery packs, the SOC of each battery pack, maximum power output of each battery pack and maximum power output of all battery packs combined.
摘要:
This invention provides a method of energizing electric vehicle (EV) power train with multiple and independently controlled battery packs. In this method, an EV can have one or more battery packs installed, only limited by the EV's physical spaces of the battery pack connector. All battery packs are interchangeable. Each battery pack has its battery management system (BMS) software and can either provide energy to the EV concurrently or individually. A typical embodiment of the invention comprises of a battery pack controller, a battery pack connector, a battery pack acting as the master (master battery pack), and optional slave battery pack(s). The battery pack controller connects electronically with the battery pack connector. The master battery pack, and optional slave battery pack(s) are mounted in the modular battery pack connector. The battery pack controller whose source is from the BMS of the master battery pack manages the charging and discharging of the master battery pack and optional slave battery pack(s).
摘要:
The invention relates to sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones compounds having formula (I) wherein R1 is selected from the group consisting of 4-methylsulfonyl, 4-aminosulfonyl, hydrogen, 2-, 3-, or 4-halogen, C1–C6-alkyl, cyclopentyl, cyclohexyl, C1–C4-alkoxy, hydroxy, cyano, nitro, amino or trifluoromethyl; R2 is selected from the group consisting of 4-methylsulfonyl, 4-aminosulfonyl, hydrogen, 2-, 3-, or 4-halogen, C1–C6-alkyl, cyclopentyl, cyclohexyl, C1–C4-alkoxy, hydroxy, cyano, nitro, amino or trifluoromethyl; and R3 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, isobutyl; provided that when R1 is a methylsulfonyl or aminosulfonyl group, R2 is any group as defined above except a methylsulfonyl or aminosulfonyl group; and when R2 is a methylsulfonyl or aminosulfonyl group, R1 is any group as defined above except a methylsulfonyl or aminosulfonyl group, also to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the medical use of such compounds in the treatment of diseases relating to the inhibition of cyclooxygenase-2 (COX-2).
摘要翻译:本发明涉及具有式(I)的含磺酰基的3,4-二芳基-3-吡咯啉-2-酮化合物,其中R 1选自4-甲基磺酰基,4-氨基磺酰基 ,氢,2-,3-或4-卤素,C 1 -C 6 - 烷基,环戊基,环己基,C 1〜 C 4 - 烷氧基,羟基,氰基,硝基,氨基或三氟甲基; R 2选自4-甲基磺酰基,4-氨基磺酰基,氢,2-,3-或4-卤素,C 1 -C 6 - 烷基,环戊基,环己基,C